Leerink Partners raises Faeth Therapeutics target price to $52 from $46
FTH•Leerink Partners raised its target price for Faeth Therapeutics to $52 from $46.
Related News
Food industry pushes back on WHO guidance for products with added colour, sweeteners
XLP•
US FDA orders new eye risk warnings for Ozempic, Zepbound
LLY•
US September wholesale inventories data
SPY•
SEGG Media Q2 revenue rises 1,584% to $3.2 million
SEGG•
Amazon AWS commits $100 million of AI and cloud technology to help organizations expand health services worldwide
AMZN•